Literature DB >> 18421792

Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.

Mariola López1, Vincent Soriano, Norma Rallón, Almudena Cascajero, Juan González-Lahoz, José M Benito.   

Abstract

A better control of viral replication in long-term non-progressors has been associated with polyfunctional CD8(+) T cell responses. However, low levels of HIV replication could be the cause rather than the consequence of enhanced immune responses in long-term non-progressors. The functional profile and the expansion ability of HIV-Gag- and HIV-Nef-specific CD8 responses were analysed measuring the production of MIP-1beta, IL-2, TNF-alpha and expression of CD107, using polychromatic flow cytometry, in 36 HIV-infected patients at baseline and after 12 months of highly active antiretroviral therapy (HAART) and complete viral suppression. Most patients presented detectable Gag and Nef responses both at baseline and after 1 year of HAART, with a significant decline after achieving viral suppression. At baseline, the majority of CD8(+) response was due to cells producing only MIP-1beta or simultaneously MIP-1beta and CD107. The functional profile did not significantly change after achieving complete viral suppression with HAART. Therefore, control of HIV-1 replication after 1 year of HAART had no significant impact on the quality of HIV-1-specific CD8 response, but the effects of treatment in long-term, or of early HAART are not known. Thus, it is still uncertain whether multifunctional CD8 responses are the cause or consequence of low plasma viremia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18421792     DOI: 10.1002/eji.200738054

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

1.  The expansion ability but not the quality of HIV-specific CD8(+) T cells is associated with protective human leucocyte antigen class I alleles in long-term non-progressors.

Authors:  Mariola López; Alejandra Peris; Vincent Soriano; Sara Lozano; José Luis Vicario; Norma I Rallón; Clara Restrepo; José M Benito
Journal:  Immunology       Date:  2011-11       Impact factor: 7.397

2.  Human immunodeficiency virus type I-specific CD8+ T cell subset abnormalities in chronic infection persist through effective antiretroviral therapy.

Authors:  Julia Pohling; Katrin Zipperlen; Natasha A Hollett; Maureen E Gallant; Michael D Grant
Journal:  BMC Infect Dis       Date:  2010-05-25       Impact factor: 3.090

3.  CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy.

Authors:  Jennifer Serwanga; Susan Mugaba; Auma Betty; Edward Pimego; Sarah Walker; Paula Munderi; Charles Gilks; Frances Gotch; Heiner Grosskurth; Pontiano Kaleebu
Journal:  AIDS Res Treat       Date:  2011-01-18

4.  Initiation of Antiretroviral Therapy (ART) at Different Stages of HIV-1 Disease Is Not Associated with the Proportion of Exhausted CD8+ T Cells.

Authors:  Sanne Skov Jensen; Anders Fomsgaard; Tine Kochendorf Larsen; Jeanette Linnea Tingstedt; Jan Gerstoft; Gitte Kronborg; Court Pedersen; Ingrid Karlsson
Journal:  PLoS One       Date:  2015-10-01       Impact factor: 3.240

5.  Vγ9Vδ2 T-Cell Polyfunctionality Is Differently Modulated in HAART-Treated HIV Patients according to CD4 T-Cell Count.

Authors:  Rita Casetti; Gabriele De Simone; Alessandra Sacchi; Alessandra Rinaldi; Domenico Viola; Chiara Agrati; Veronica Bordoni; Eleonora Cimini; Nicola Tumino; Francesca Besi; Federico Martini
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

6.  Interleukin-12p70 expression by dendritic cells of HIV-1-infected patients fails to stimulate gag-specific immune responses.

Authors:  Ellen Van Gulck; Nathalie Cools; Derek Atkinson; Lotte Bracke; Katleen Vereecken; Marc Vekemans; Viggo F I Van Tendeloo; Zwi N Berneman; Guido Vanham
Journal:  Clin Dev Immunol       Date:  2012-07-12

7.  Magnitude and complexity of rectal mucosa HIV-1-specific CD8+ T-cell responses during chronic infection reflect clinical status.

Authors:  J William Critchfield; Delandy H Young; Timothy L Hayes; Jerome V Braun; Juan C Garcia; Richard B Pollard; Barbara L Shacklett
Journal:  PLoS One       Date:  2008-10-30       Impact factor: 3.240

8.  Levels of CD56+TIM-3- effector CD8 T cells distinguish HIV natural virus suppressors from patients receiving antiretroviral therapy.

Authors:  Bhawna Poonia; C David Pauza
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

9.  Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.

Authors:  Ai Kawana-Tachikawa; Josep M Llibre; Isabel Bravo; Roser Escrig; Beatriz Mothe; Jordi Puig; Maria C Puertas; Javier Martinez-Picado; Julia Blanco; Christian Manzardo; Jose M Miro; Aikichi Iwamoto; Anton L Pozniak; Jose M Gatell; Bonaventura Clotet; Christian Brander
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

Review 10.  The enduring tale of T cells in HIV immunopathogenesis.

Authors:  Madhu Vajpayee; Neema Negi; Sravya Kurapati
Journal:  Indian J Med Res       Date:  2013-11       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.